The impact of PSMA PET–based eligibility criteria used in the prospective phase II TheraP trial in metastatic castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen–targeted radioligand therapy

Download full text files

Export metadata

Statistics

Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Amir Karimzadeh, Matthias M. HeckGND, Robert Tauber, Esteban Solaris, Stephan Nekolla, Karina Knorr, Bernhard Haller, Calogero D'Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher
URN:urn:nbn:de:bvb:384-opus4-1244206
Frontdoor URLhttps://opus.bibliothek.uni-augsburg.de/opus4/124420
ISSN:0161-5505OPAC
ISSN:2159-662XOPAC
Parent Title (English):Journal of Nuclear Medicine
Publisher:Society of Nuclear Medicine and Molecular Imaging
Place of publication:New York, NY
Type:Article
Language:English
Year of first Publication:2023
Publishing Institution:Universität Augsburg
Release Date:2025/08/14
Volume:64
Issue:8
First Page:1252
Last Page:1258
DOI:https://doi.org/10.2967/jnumed.122.265346
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Urologie (Weckermann)
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):Deutsches Urheberrecht